Company / CIK 0001806952
Lyell Immunopharma, Inc.
- Ticker
- LYEL
- Size, estimated from filings
- Small cap ($300M – $2B)
- Insiders on file
- 8
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 12, 2026
Lyell Immunopharma, Inc. (LYEL) has 8 insiders on file who disclosed 11 transactions in the last 12 months (0 open-market buys, 9 sales, about $215K at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
Lyell Immunopharma, Inc. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
6 people account for the disclosed buying and selling in Lyell Immunopharma, Inc. over the last 12 months; the most active is Seely Lynn with $155K.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Aguirre Jarrad Mattieu | Chief Medical Officer | 2 | 0 | 1 | October 13, 2026 |
| Shook David | Chief Medical Officer | 1 | 0 | 1 | September 10, 2026 |
| Seely Lynn | President and CEO | 2 | 0 | 2 | August 25, 2026 |
| Hill Stephen J. | Chief Operating Officer | 2 | 0 | 2 | August 25, 2026 |
| Lee Gary K. | Chief Scientific Officer | 2 | 0 | 2 | August 25, 2026 |
| Bulis Veronica Sanchez | VP, Corporate Controller | 1 | 0 | 1 | August 11, 2026 |
| Innovative Cellular Therapeutics Holdings Ltd | Insider | 1 | 0 | 0 | July 27, 2026 |
| GLAXOSMITHKLINE PLC | Insider | 2 | 0 | 0 | December 15, 2025 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aguirre Jarrad Mattieu | LYEL | Sell S | October 12, 2026 | October 13, 2026 | 1d | 422 | $9 | $3,642 | Form 4 ↗ | ||
| Aguirre Jarrad Mattieu | LYEL | Other A | September 10, 2026 | September 10, 2026 | 0d | 47,500 | — | — | derivative | Form 4 ↗ | |
| Shook David | LYEL | Sell S | September 10, 2026 | September 10, 2026 | 0d | 500 | $13 | $6,350 | Form 4 ↗ | ||
| Lee Gary K. | LYEL | Sell S | August 21, 2026 | August 25, 2026 | 4d | 1,457 | $16 | $23K | Form 4 ↗ | ||
| Hill Stephen J. | LYEL | Sell S | August 21, 2026 | August 25, 2026 | 4d | 989 | $16 | $15K | Form 4 ↗ | ||
| Seely Lynn | LYEL | Sell S | August 21, 2026 | August 25, 2026 | 4d | 9,589 | $16 | $149K | Form 4 ↗ | ||
| Seely Lynn | LYEL | Sell S | August 10, 2026 | August 11, 2026 | 1d | 390 | $14 | $5,593 | Form 4 ↗ | ||
| Hill Stephen J. | LYEL | Sell S | August 10, 2026 | August 11, 2026 | 1d | 89 | $14 | $1,276 | Form 4 ↗ | ||
| Lee Gary K. | LYEL | Sell S | August 10, 2026 | August 11, 2026 | 1d | 131 | $14 | $1,879 | Form 4 ↗ | ||
| Bulis Veronica Sanchez | LYEL | Sell S | August 10, 2026 | August 11, 2026 | 1d | 621 | $14 | $8,905 | Form 4 ↗ | ||
| Innovative Cellular Therapeutics Holdings Ltd | LYEL | Other J | July 27, 2026 | July 27, 2026 | 0d | 44,000 | — | — | Form 4 ↗ | ||
| GLAXOSMITHKLINE PLC | LYEL | Exchange C | June 21, 2021 | June 23, 2021 | 2d | 30,253,189 | — | — | indirectderivative | Form 4 ↗ | |
| GLAXOSMITHKLINE PLC | LYEL | Exchange C | June 21, 2021 | June 23, 2021 | 2d | 30,253,189 | — | — | indirect | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "Lyell Immunopharma, Inc.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "Lyell Immunopharma, Inc." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Related companies
Companies whose stock was traded by the same people who traded LYEL, by number of filers in common. It shows overlap in public filings and nothing else.
- Wave Life Sciences, Inc. WVE 1 filer in common
- BICYCLE THERAPEUTICS PLC BCYC 1 filer in common
- CVRx, Inc. CVRX 1 filer in common
- Innoviva, Inc. INVA 1 filer in common
- Decibel Therapeutics, Inc. DBTX 1 filer in common
- GENOCEA BIOSCIENCES, INC. GNCA 1 filer in common
- Theravance Biopharma, Inc. TBPH 1 filer in common
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 12 | 13 | June 23, 2021 | October 13, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.